XENE Xenon Pharmaceuticals Inc.
FY2025 10-K
Xenon Pharmaceuticals Inc. (XENE) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: neuroscience-focused biopharma discovering and commercializing novel ion channel modulators for neurological and psychiatric disorders
- • New emphasis on azetukalner in Phase 3 for epilepsy (FOS and PGTCS) and depression (MDD and BPD), with multiple late-stage studies ongoing
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided section
- • No segment performance data available
Risk Factors
- • Regulatory risk: alignment with Japan’s PMDA to enroll ~60 of 360 X-TOLE3 participants in Japan, affecting regulatory submission timing
- • Macroeconomic risk: foreign exchange exposure to Canadian dollar fluctuations impacting monetary assets and liabilities
Financial SummaryXBRL
Revenue
$8M
Net Income
-$346M
Operating Margin
-4974.3%
Net Margin
-4612.1%
ROE
-59.5%
Total Assets
$633M
EPS (Diluted)
$-4.36
Operating Cash Flow
-$279M
Source: XBRL data from Xenon Pharmaceuticals Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Xenon Pharmaceuticals Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.